EP3612274A4 - Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout - Google Patents

Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout Download PDF

Info

Publication number
EP3612274A4
EP3612274A4 EP18787621.4A EP18787621A EP3612274A4 EP 3612274 A4 EP3612274 A4 EP 3612274A4 EP 18787621 A EP18787621 A EP 18787621A EP 3612274 A4 EP3612274 A4 EP 3612274A4
Authority
EP
European Patent Office
Prior art keywords
hyperpigmentation
gout
solid tumors
buffering agents
systemic administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18787621.4A
Other languages
German (de)
French (fr)
Other versions
EP3612274A1 (en
Inventor
Bruce J. Sand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ampersand Biopharmaceuticals LLC
Original Assignee
Ampersand Biopharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ampersand Biopharmaceuticals LLC filed Critical Ampersand Biopharmaceuticals LLC
Publication of EP3612274A1 publication Critical patent/EP3612274A1/en
Publication of EP3612274A4 publication Critical patent/EP3612274A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18787621.4A 2017-04-17 2018-04-17 Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout Withdrawn EP3612274A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762602227P 2017-04-17 2017-04-17
US201762602359P 2017-04-20 2017-04-20
US201762602358P 2017-04-20 2017-04-20
US201762559360P 2017-09-15 2017-09-15
US201762559947P 2017-09-18 2017-09-18
US201762562725P 2017-09-25 2017-09-25
US201762609982P 2017-12-22 2017-12-22
US201862639904P 2018-03-07 2018-03-07
PCT/US2018/028017 WO2018195111A1 (en) 2017-04-17 2018-04-17 Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout

Publications (2)

Publication Number Publication Date
EP3612274A1 EP3612274A1 (en) 2020-02-26
EP3612274A4 true EP3612274A4 (en) 2021-05-26

Family

ID=63856054

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18787621.4A Withdrawn EP3612274A4 (en) 2017-04-17 2018-04-17 Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout

Country Status (7)

Country Link
EP (1) EP3612274A4 (en)
JP (1) JP2020516690A (en)
KR (1) KR20200042440A (en)
CN (1) CN111093774A (en)
AU (3) AU2018255294B2 (en)
MX (1) MX2019012385A (en)
WO (1) WO2018195111A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015371308A1 (en) 2014-12-23 2017-08-03 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
US20190083527A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Method of administration and treatment
WO2019075492A1 (en) * 2017-09-25 2019-04-18 Ampersand Biopharmaceuticals, Inc. Topical applications of withaferin a
US20210386906A1 (en) * 2018-10-23 2021-12-16 Dyve Biosciences, Inc. Methods and formulations for transdermal administration of dermal contouring agents
KR20210124958A (en) * 2018-11-02 2021-10-15 앰퍼샌드 바이오파마슈티컬스, 인코포레이티드 Formulations and Methods for Risk Potential Management of Cation Overload and Electrolyte Imbalance Using Topically Applied Buffers (BUFFERS)
US20210059955A1 (en) * 2019-08-26 2021-03-04 RL Patents, LLC Systems and methods for decrystallization of uric acid
US20230330041A1 (en) * 2020-08-27 2023-10-19 Beijing Changsheng Pharmaceutical Technology Co., Ltd. Application of tris (hydroxymethyl) aminomethane pharmaceutically acceptable salt to drugs for treating hyperuricemia
CN113181149A (en) * 2021-06-11 2021-07-30 北京畅盛医药科技有限公司 External skin medicinal preparation for treating gouty arthritis
CN116539880B (en) * 2022-12-05 2023-12-08 四川大学华西医院 Application of reagent for detecting metabolites and/or tissue proteins in preparation of gouty arthritis screening kit
CN116284814A (en) * 2023-01-17 2023-06-23 杭州三式化妆品有限公司 Supermolecule tranexamic acid glycolate ion salt and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228374A1 (en) * 2002-06-07 2003-12-11 Pesacreta Thomas C. Topical treatment for skin irritation
WO2004008887A1 (en) * 2002-07-23 2004-01-29 Phoenix Eagle Company Pty Ltd Fruit and/or vegetable derived composition
CN106236937A (en) * 2016-08-31 2016-12-21 腾冲恒益东山休闲度假有限责任公司 The bath foam of gouty arthritis can be alleviated

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176918A (en) * 1990-12-20 1993-01-05 Jones Jeffry L Topical medicament
DE69710182T2 (en) * 1996-04-04 2002-08-29 F. Hoffmann-La Roche Ag, Basel USE OF TETRAHYDROBETACARBOLIN DERIVATIVES FOR PREVENTING METASTASIS
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
WO2007103555A2 (en) * 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
WO2010030395A2 (en) * 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof
CN101897784A (en) * 2009-05-27 2010-12-01 北京因科瑞斯医药科技有限公司 Chinese medicinal composition for treating gout and preparation method thereof
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
WO2011066379A2 (en) * 2009-11-24 2011-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION
US8518871B2 (en) * 2010-11-09 2013-08-27 The Regents Of The University Of California Skin permeating and cell entering (SPACE) peptides and methods of use thereof
JP5696299B2 (en) * 2011-03-29 2015-04-08 ネオケミア株式会社 Antitumor agent containing carbon dioxide as an active ingredient
CA2868461C (en) * 2012-03-28 2021-01-05 University Of Central Florida Research Foundation, Inc. Anti-metatstatic agents predicated upon polyamine-macrocyclic conjugates
AU2015371308A1 (en) * 2014-12-23 2017-08-03 Intellectual Property Associates, Llc Methods and formulations for transdermal administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228374A1 (en) * 2002-06-07 2003-12-11 Pesacreta Thomas C. Topical treatment for skin irritation
WO2004008887A1 (en) * 2002-07-23 2004-01-29 Phoenix Eagle Company Pty Ltd Fruit and/or vegetable derived composition
CN106236937A (en) * 2016-08-31 2016-12-21 腾冲恒益东山休闲度假有限责任公司 The bath foam of gouty arthritis can be alleviated

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Baking Soda Treatment for Gout", 5 November 2016 (2016-11-05), pages 1 - 3, XP055765385, Retrieved from the Internet <URL:https://web.archive.org/web/20161110122944/https://www.earthclinic.com/baking-soda-for-gout.html> [retrieved on 20210115] *
R. VERDOLINI ET AL: "Old fashioned sodium bicarbonate baths for the treatment of psoriasis in the era of futuristic biologics: An old ally to be rescued", JOURNAL OF DERMATOLOGICAL TREATMENT, vol. 16, no. 1, 12 February 2005 (2005-02-12), UK, pages 26 - 29, XP055765406, ISSN: 0954-6634, DOI: 10.1080/09546630410024862 *

Also Published As

Publication number Publication date
JP2020516690A (en) 2020-06-11
AU2023254920A1 (en) 2023-11-16
AU2022241559B2 (en) 2023-07-27
WO2018195111A1 (en) 2018-10-25
EP3612274A1 (en) 2020-02-26
MX2019012385A (en) 2022-03-15
KR20200042440A (en) 2020-04-23
AU2018255294B2 (en) 2022-07-28
CN111093774A (en) 2020-05-01
AU2022241559A1 (en) 2022-10-27
AU2018255294A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
EP3612274A4 (en) Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout
EP3607387A4 (en) Segmented imaging directional backlights
EP3658557A4 (en) Tyk2 inhibitors and uses thereof
EP3567742A4 (en) Channel state information feedback and determination methods, and device
EP3355637A4 (en) Information sending, information determining and relationship determining methods and devices
EP3344624B8 (en) Tyk2 inhibitors and uses thereof
EP3178286A4 (en) Systems, methods, and devices for proximity services for multi-carrier capable mobile devices
EP3592746A4 (en) Tyk2 inhibitors, uses, and methods for production thereof
EP3262049A4 (en) Tyk2 inhibitors and uses thereof
EP3269124A4 (en) Systems and methods for web api communications
EP3281168A4 (en) Discovering and publishing api information
EP3536732A4 (en) Polyimide precursor composition and polyimide film using same
EP3571769A4 (en) Data segment into packets for channel encoding
EP3311609A4 (en) Systems and methods for improved data speeds for wireless devices
EP3719050A4 (en) Compound and tablet
EP3479828A4 (en) Drug composition for parenteral administration
EP3184113A4 (en) Pharmaceutical composition, comprising gold compound, for preventing or treating liver fibrosis or liver cirrhosis
SG10202111088SA (en) Non-magnetic substrate for magnetic disk, and magnetic disk
EP3204424A4 (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
EP3193406A4 (en) Multipolar lead component, and connection device for substrate
EP3369207A4 (en) An information secure protocol for mobile proactive secret sharing with near-optimal resilience
EP3332242A4 (en) Photoluminescent authentication devices, systems, and methods
EP3564242A4 (en) Compound for selectively inhibiting kinase and use thereof
EP3628961A4 (en) Borehole plugging device
EP3538101A4 (en) Inhibitors of cancer invasion, attachment, and/or metastasis

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/06 20060101ALI20210121BHEP

Ipc: A61K 9/06 20060101AFI20210121BHEP

Ipc: A61K 45/06 20060101ALI20210121BHEP

Ipc: A61K 33/42 20060101ALI20210121BHEP

Ipc: A61K 47/02 20060101ALI20210121BHEP

Ipc: A61K 33/10 20060101ALI20210121BHEP

Ipc: A61K 9/00 20060101ALI20210121BHEP

Ipc: A61P 17/00 20060101ALI20210121BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0035040000

Ipc: A61K0009060000

A4 Supplementary search report drawn up and despatched

Effective date: 20210429

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/06 20060101AFI20210422BHEP

Ipc: A61K 9/00 20060101ALI20210422BHEP

Ipc: A61P 19/06 20060101ALI20210422BHEP

Ipc: A61K 33/42 20060101ALI20210422BHEP

Ipc: A61K 47/02 20060101ALI20210422BHEP

Ipc: A61K 33/10 20060101ALI20210422BHEP

Ipc: A61K 45/06 20060101ALI20210422BHEP

Ipc: A61P 17/00 20060101ALI20210422BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230425

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230524

18W Application withdrawn

Effective date: 20230601